In recent years, tumor immunotherapy such as anti-PD-1/PD-L1/CTLA-4 monoclonal antibody and chimeric antigen receptor T-cell (CAR-T) immunotherapy has extensively been attentioned as an important part of combined therapy. This evidence concerns the gene CD274 and neoplasm.